Latin America Oncology Device Market Report

Latin America Oncology Device Market Size

The Latin America oncology device market was valued at USD 6.51 billion in 2025, is estimated to reach USD 6.97 billion in 2026, and is projected to reach USD 12.06 billion by 2034, growing at a CAGR of 7.09% from 2026 to 2034.

Oncology device refers to the medical technologies designed for the diagnosis, treatment, and monitoring of cancer, including radiation therapy systems, surgical oncology devices, biopsy equipment, and imaging modalities. Unlike broad healthcare segments, this domain is shaped by the convergence of technological innovation and clinical necessity in response to rising cancer burdens. As per the Pan American Health Organization, cancer accounts for over 1.4 million new cases annually across Latin America, with breast, prostate, and colorectal cancers dominating incidence rates. Healthcare expenditure in countries like Mexico remains below 7% of GDP, constraining infrastructure development. Moreover, the International Agency for Research on Cancer projects that mortality rates from cancer in the region could increase by nearly 70% over the next two decades due to delayed diagnoses and uneven access to advanced care, underlining the urgency for scalable oncology technologies.

MARKET DRIVERS

Rising Cancer Burden and Adoption of Advanced Oncology Devices

The escalating prevalence of cancer, particularly in aging populations and urban centers is a critical driver of demand in the Latin America oncology device market. According to the International Agency for Research on Cancer, an estimated 1.4 million new cancer cases were diagnosed in Latin America, with Brazil alone contributing over 620,000 cases. Prostate cancer incidence in men has surged over the past decade, while breast cancer remains the leading cause of cancer-related deaths among women. Urbanization and lifestyle shifts, such as increased tobacco use, sedentary behavior, and poor dietary habits, are amplifying risk factors. A notable share of cancer deaths in the region occur prematurely, before age 70, largely due to late-stage diagnosis. This growing disease burden compels healthcare systems to adopt advanced diagnostic and therapeutic devices, including digital mammography systems, automated biopsy platforms, and linear accelerators, thereby accelerating procurement and deployment across public and private facilities.

Healthcare Infrastructure Expansion and Government Cancer Control Initiatives

The expansion of healthcare infrastructure and government-led cancer control initiatives across key Latin American nations is another pivotal demand driver. Argentina has modernized regional oncology centers, integrating advanced radiation therapy devices. Furthermore, as per the PAHO, Latin America currently has fewer than 5 radiation therapy machines per million people, significantly below the WHO-recommended benchmark of 8–10 units per million. This deficit has prompted public tenders and cross-border collaborations with device manufacturers, fueling demand for linear accelerators, brachytherapy units, and PET-CT scanners, particularly in underserved regions.

MARKET RESTRAINTS

Limited Healthcare Access and High Out-of-Pocket Expenditures

The persistent inequity in healthcare access across socioeconomic and geographic lines is a major restraint in the Latin America oncology device market. Also, a portion of the region’s population lacks access to essential diagnostic services, with rural areas in countries like Bolivia, Guatemala, and parts of the Amazon basin facing severe shortages of oncology-trained personnel and equipment. The World Bank points out that out-of-pocket health expenditures constitute over 40% of total health spending in several Latin American countries, deterring patients from pursuing costly cancer treatments. This fragmented access limits the effective utilization of high-end oncology devices, even when procured, undermining return on investment for healthcare providers and discouraging private sector participation in remote regions.

Regulatory Fragmentation and Prolonged Approval Timelines

Regulatory fragmentation and protracted approval timelines significantly hinder the commercialization of oncology devices in Latin America. As per the Pan American Health Organization, regulatory processes vary widely across countries, with Brazil’s ANVISA requiring several months for high-class medical device registration, while Argentina’s ANMAT and Colombia’s Invima impose differing technical and clinical requirements. This inconsistency deters multinational manufacturers from launching next-generation devices in the region, delaying patient access. Additionally, frequent changes in import tariffs and local content regulations further escalate time-to-market and operational costs, restricting the availability of innovative oncology technologies.

MARKET OPPORTUNITIES

Digital Pathology and Telemedicine to Bridge Diagnostic Gaps

The integration of telemedicine and digital pathology to bridge diagnostic gaps in remote oncology care is a significant opportunity. Millions of people in Latin America live in areas with limited or no access to specialized pathology services. However, pilot programs have demonstrated that digitized biopsy imaging and AI-assisted analysis can reduce diagnostic turnaround times. Also, scaling digital diagnostics could save health systems a significant amount annually by reducing unnecessary referrals and repeat testing. This digital transformation creates a fertile ground for companies offering cloud-based imaging platforms, AI-driven radiology tools, and portable biopsy scanners tailored to low-bandwidth environments.

Expanding Radiotherapy Infrastructure through Public-Private Partnerships

Public-private partnerships (PPPs) aimed at expanding radiotherapy infrastructure are another emerging opportunity. As per the International Atomic Energy Agency, Latin America faces a deficit of nearly 1,200 radiotherapy machines to meet WHO standards. In response, some countries have adopted PPP models to finance and operate oncology centers. As per the World Bank, PPPs in healthcare infrastructure have been increasing annually in Latin America since 2020, signaling increasing institutional confidence. These collaborations not only alleviate fiscal pressure on governments but also ensure technology transfer, staff training, and sustainable service delivery, creating long-term avenues for device manufacturers.

MARKET CHALLENGES

Shortage of Skilled Oncology Professionals Limiting Device Utilization

The shortage of specialized oncology healthcare professionals capable of operating advanced devices is a key challenge. A considerable portion of radiotherapy machines in the region operate below capacity due to insufficient trained personnel. Brazil, despite having the largest number of linear accelerators in the region, faces a vacancy rate in radiotherapy technician positions. This human resource gap impedes the effective utilization of capital-intensive oncology devices, leading to underperformance and increased maintenance costs. Training programs remain limited, with fewer accredited medical physics schools across the region, constraining workforce development.

Economic Volatility and Currency Fluctuations Hindering Device Procurement

Sustained economic volatility and currency fluctuations present a systemic challenge to the procurement and maintenance of oncology devices. As per the International Monetary Fund, inflation rates in Argentina exceeded 140% in 2023, while the Argentine peso lost over 60% of its value against the US dollar within a single year. This devaluation drastically increases the cost of importing high-tech medical equipment, which are predominantly priced in USD. In Venezuela, hyperinflation has rendered long-term healthcare planning nearly impossible, disrupting supply chains for critical device components and spare parts. These macroeconomic instabilities undermine budget predictability for hospitals and deter multinational manufacturers from establishing regional service hubs, threatening the continuity of oncology care.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Application Insights

The radiation therapy segment stood as the dominant application in the Latin America oncology device market by capturing 36.2% of total revenue in 2024. This lead position of the segment is credited to the high clinical reliance on radiotherapy across multiple cancer types, particularly cervical, prostate, and head and neck cancers, which are prevalent in the region. According to the International Atomic Energy Agency, over 50% of cancer patients in Latin America require radiotherapy at some point during their treatment, a proportion consistent with global standards. In some countries, radiotherapy is integrated into national cancer treatment protocols for most eligible cases, reinforcing institutional procurement of linear accelerators and brachytherapy units. Besides, the scarcity of surgical oncology infrastructure in rural areas elevates the dependence on non-invasive modalities, making radiation therapy a cornerstone of regional cancer care delivery. The expansion of public-sector radiotherapy programs is another critical factor consolidating this segment’s dominance. Brazil’s Ministry of Health operates over 180 radiotherapy centers under its Unified Health System (SUS), serving more than 200,000 patients annually. In Brazil, the country has increased its linear accelerator fleet since 2018 to meet rising demand. These state-backed initiatives ensure sustained capital investment, reinforcing radiation therapy’s entrenched position in the oncology device ecosystem.

The diagnostic Imaging segment is emerging as the fastest-growing application in the Latin America oncology device market and is projected to expand at a CAGR of 11.7% from 2026 to 2034. This acceleration is driven by the urgent need for early cancer detection, as a significant proportion of patients present with advanced-stage disease due to limited screening access. Like, most of the breast and cervical cancer cases in the region are diagnosed at stage III or IV, drastically reducing survival rates. In response, governments are prioritizing imaging-based screening programs. An additional pivotal driver is the integration of artificial intelligence (AI) and teleradiology into diagnostic workflows, particularly in remote areas. Moreover, AI-enabled imaging platforms have improved diagnostic accuracy in pilot programs across Central America. Furthermore, the expansion of mobile imaging units has enhanced geographic accessibility. These technological and logistical advancements are transforming diagnostic imaging into a high-growth, scalable component of oncology care.

By Device Type Insights

The Diagnostic Imaging Devices segment represents the largest in the Latin America oncology device market by device type and accounted for an estimated 35.6% of total market value in 2024. This dominance is primarily fueled by the escalating demand for advanced imaging modalities such as MRI, PET-CT, and digital mammography systems to support early cancer diagnosis. Like, only a limited portion of Latin American women have access to regular breast cancer screening, prompting governments to scale imaging infrastructure. Brazil, for instance, increased its fleet of digital mammography units. The integration of hybrid imaging systems is another key factor reinforcing market leadership. Additionally, Latin America currently has fewer MRI units per million people, well below than that of the OECD, creating substantial unmet demand. This deficit, coupled with rising cancer incidence, ensures sustained procurement of imaging devices, solidifying their position as the most valuable device category.

The Radiotherapy Equipment segment is the fastest-growing device type in the Latin America oncology device market and is anticipated to grow at a CAGR of 10.9% from 2026 to 2034. This surge is propelled by a severe shortage of radiotherapy infrastructure relative to cancer burden. Brazil, despite being the region’s largest market, requires additional linear accelerators to meet demand. A different catalyst is the modernization of aging radiotherapy fleets. These replacement cycles, combined with new installations in previously unserved regions, are accelerating capital expenditure on radiotherapy hardware, positioning this segment for sustained high growth.

By End User Insights

The hospitals segment constituted the prominent end-user in the Latin America oncology device market by commanding a 62.6% of the total share in 2024. This preeminence is anchored in their role as primary hubs for comprehensive cancer care, housing multidisciplinary teams and advanced technological infrastructure. Also, most cancer treatments in the region, including surgery, chemotherapy, and radiotherapy, are administered within hospital settings, particularly in national and regional referral centers. Brazil’s public hospital network, part of the SUS system, performs a large number of oncology procedures annually. The concentration of high-cost devices within hospitals further entrenches their dominance. A single tertiary care hospital in São Paulo may house multiple linear accelerators, MRI machines, and surgical robotics systems, representing multimillion-dollar investments. Besides, public hospitals in countries like Mexico and Colombia receive dedicated federal funding for oncology equipment procurement, ensuring continued capital inflow. These institutional advantages, scale, funding access, and regulatory compliance, make hospitals the central node in the oncology device distribution chain.

The Home Care Settings segment is emerging as the fastest-growing end-user in the Latin America oncology device market and is projected to grow at a CAGR of 13.4% from 2026 to 2034. This expansion is driven by the increasing adoption of portable and patient-friendly supportive care devices for symptom management outside clinical environments. Moreover, a notable share of cancer patients in urban centers receive palliative care at home, supported by devices such as portable infusion pumps, wearable pain monitors, and home oxygen concentrators. A different key factor is the economic burden of prolonged hospitalization. Additionally, companies have launched Latin America-specific portable infusion systems. These developments, combined with rising patient preference for comfort and autonomy, are catalyzing a structural shift toward decentralized oncology care delivery.

By Technology Insights

The Radiotherapy segment commands the technology part in the Latin America oncology device market by holding an estimated 52.5% share in 2025. This dominance is rooted in its established role as a primary or adjuvant treatment for a wide range of solid tumors, including prostate, cervical, and head and neck cancers, which are highly prevalent in the region. According to the International Agency for Research on Cancer, over 700,000 new cases of radiotherapy-sensitive cancers are diagnosed annually in Latin America, necessitating widespread clinical deployment of external beam and brachytherapy systems. The institutionalization of radiotherapy in national cancer control plans further strengthened its position. Brazil’s National Cancer Plan mandates radiotherapy access within 60 days of diagnosis. Given its entrenched clinical utility and policy backing, radiotherapy remains the technological backbone of oncology care in Latin America.

The cryoablation segment is the fastest-growing technology in the Latin America oncology device market and is expected to grow at a CAGR of 12.8% from 2026 to 2034. This rapid ascent is driven by its minimally invasive nature and suitability for treating early-stage tumors in patients who are not surgical candidates. The expansion of interventional radiology departments in major hospitals is a key enabler. Chile’s public health system has trained several interventional radiologists in ablation techniques since 2021. The average cost of cryoablation is lower than surgical resection, making it economically attractive for public payers. Additionally, device manufacturers like Boston Scientific and Medtronic have introduced cost-optimized cryoprobes tailored for Latin American markets. These clinical, economic, and commercial factors are accelerating the adoption of cryoablation as a preferred alternative to invasive surgery.

COUNTRY-LEVEL ANALYSIS

Brazil Oncology Device Market Insights

Brazil spearheaded the Latin America oncology device market by accounting for 45.7% of total regional revenue in 2024. As the region’s most populous and economically developed nation, Brazil serves as the primary hub for oncology technology adoption, regulatory activity, and clinical research. The country faces a significant cancer burden. In response, the Ministry of Health has expanded the SUS network to include radiotherapy centers and digital mammography units. Public investment remains a cornerstone of market growth. Brazil allocated a substantial amount to cancer control in 2023, with millions directed toward medical device procurement. Despite challenges like regional disparities and budget volatility, Brazil’s scale, infrastructure, and policy framework solidify its leadership in the regional oncology device landscape.

Mexico Oncology Device Market Insights

Mexico is another key market for oncology devices in Latin America. The country’s position is shaped by a growing cancer incidence and a concerted push to strengthen public oncology infrastructure. According to the National Institute of Public Health of Mexico, cancer surpassed cardiovascular diseases as the leading cause of death in 2022, with around 90,000-100,000 fatalities annually. Lung, breast, and colorectal cancers account for nearly half of all cases. Despite persistent challenges in rural coverage, Mexico’s strategic investments and high disease burden position it as a critical growth market.

Argentina Oncology Device Market Insights

Argentina commands a significant share of the Latin America oncology device market. The country’s oncology landscape is characterized by a relatively advanced healthcare system in urban centers, though constrained by economic instability. According to Argentina’s National Cancer Institute (INEN), around 130, 00 new cancer cases were diagnosed in 2023, with breast and prostate cancers leading incidence rates. Public-private collaboration has been instrumental in sustaining device access. With support from the International Atomic Energy Agency, Argentina modernized six regional oncology centers between 2021 and 2023, installing advanced brachytherapy and teletherapy units. These efforts preserve Argentina’s role as a mid-tier but technologically active market.

Chile Oncology Device Market Insights

Chile is distinguished by its high healthcare standards and digital innovation. The country’s oncology system benefits from strong governance and targeted investment, despite a smaller population base. According to Chile’s Ministry of Health, cancer is responsible for 28% of all deaths, with close to 60,000 new cases diagnosed annually. Chile has emerged as a leader in AI-driven diagnostics and teleradiology. In 2022, the government deployed an AI-powered lung cancer screening platform across hospitals, reducing diagnostic delays. The country also boasts one of the highest MRI densities in Latin America, with 15 units per million people. These advancements position Chile as a model for technology integration in oncology care.

COMPETITIVE LANDSCAPE

The competition in the Latin America oncology device market is intensifying as global leaders and regional players vie for influence amid growing cancer burdens and uneven healthcare access. Multinational corporations dominate through advanced radiotherapy and imaging technologies, while local distributors and service providers gain ground by offering cost-effective maintenance and training. Differentiation arises from post-sales support, regulatory agility, and adaptability to public procurement cycles. Companies are increasingly focusing on value-based solutions, integrating AI and telemedicine to overcome infrastructure gaps. Strategic collaborations with public institutions and international agencies enhance credibility and access. However, economic volatility and fragmented regulatory landscapes challenge uniform market penetration. As demand for early diagnosis and precision treatment rises, competitive advantage is shifting toward comprehensive care ecosystems rather than standalone devices, fostering innovation and long-term partnerships.

KEY MARKET PLAYERS

Some of the noteworthy companies in the Latin America oncology device market profiled in this report are

• Siemens Healthineers
• GE Healthcare
• Varian Medical Systems
• Accuray
• Boston Scientific
• CRAD
• Medtronic
• Bayer
• Hologic
• Thermo Fisher Scientific
• Philips
• Elekta
• NantHealth
• Toshiba Medical Systems

TOP LEADING PLAYERS IN THE MARKET

• Varian Medical Systems maintains a dominant presence in the Latin America oncology device market through its comprehensive portfolio of radiotherapy and software solutions. The company has strategically expanded its footprint by collaborating with public health institutions in Brazil, Mexico, and Colombia to modernize radiotherapy infrastructure. In 2023, Varian deployed its Ethos therapy system in select private oncology centers in Chile and Argentina, showcasing adaptive radiotherapy capabilities tailored for complex tumor cases. The company also launched training programs with local medical associations to enhance clinical proficiency in AI-driven treatment planning. By integrating its ARIA oncology information system with regional hospital networks, Varian has strengthened care coordination. Its partnership with the International Atomic Energy Agency on technical capacity building further solidifies its role as a key enabler of advanced cancer care across underserved regions.
• Elekta has established a robust position in Latin America by focusing on integrated solutions for radiation oncology and surgical planning. The company has deepened its engagement with public healthcare systems, supplying linear accelerators and Monaco treatment planning systems to national cancer institutes in Mexico and Brazil. In 2022, Elekta initiated a service expansion program across Central America, deploying mobile maintenance units to improve uptime for existing installations. It also collaborated with the Pan American Health Organization on a regional initiative to standardize radiotherapy protocols. Elekta’s recent introduction of the Unity MR-linac in高端 centers in São Paulo and Bogotá highlights its commitment to bringing cutting-edge technology to the region. Additionally, the company has invested in localized customer support hubs in Colombia and Chile, enhancing response times and technical training, thereby reinforcing long-term relationships with clinical and administrative stakeholders.
• GE Healthcare plays a pivotal role in advancing diagnostic imaging within the Latin America oncology device market, offering PET-CT, MRI, and digital mammography systems essential for early cancer detection. The company has intensified its outreach to public hospitals by providing flexible financing models for high-end imaging equipment in Brazil and Peru. In 2023, GE launched the Senographe Pristina with AI-powered breast tomosynthesis in Mexico, significantly improving lesion detection rates in dense breast tissue. It also introduced Edison AI platform integrations in several oncology centers, enabling faster image analysis and reporting. GE HealthCare partnered with Argentina’s Ministry of Health to deploy mobile PET-CT units in remote provinces, expanding access to precision diagnostics. Its ongoing collaboration with local universities for radiologist training ensures optimal utilization of its technologies, strengthening its reputation as a clinical and technological partner in oncology care transformation.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players in the Latin America oncology device market are leveraging strategic partnerships, localized service networks, technology adaptation, public-sector engagement, and digital integration to strengthen their positions. Companies are increasingly collaborating with government health agencies and international organizations to align with national cancer control programs. Expanding service and maintenance infrastructure ensures the reliability of high-cost devices in regions with limited technical expertise. Firms are tailoring product offerings to regional economic conditions, including cost-optimized models and flexible financing. Digital health integration, such as AI-driven diagnostics and cloud-based oncology platforms, is enhancing clinical utility. Additionally, manufacturers are investing in training programs for medical professionals to improve adoption and operational efficiency, ensuring sustainable technology deployment across diverse healthcare environments.

RECENT MARKET DEVELOPMENTS

• In March 2023, Varian Medical Systems launched its Ethos therapy platform in private oncology centers across Argentina and Chile, introducing AI-driven adaptive radiotherapy to enhance treatment precision for complex tumors and improve clinical outcomes in high-income patient segments.
• In July 2022, Elekta AB expanded its service operations in Central America by deploying mobile maintenance units across Guatemala, Honduras, and El Salvador, ensuring faster technical support and minimizing downtime for radiotherapy systems in underserved public hospitals.
• In November 2023, GE HealthCare partnered with Argentina’s Ministry of Health to deploy ten mobile PET-CT units in remote provinces, significantly expanding access to advanced cancer diagnostics and reinforcing its leadership in diagnostic imaging across geographically isolated regions.
• In May 2024, Siemens Healthineers, following its acquisition of Varian, integrated the ARIA oncology information system with Brazil’s public hospital network in São Paulo, enabling seamless data flow between diagnosis, treatment planning, and delivery for over 50,000 patients annually.
• In January 2022, Elekta initiated a training alliance with the Latin American Society of Radiation Oncology, launching a certification program for 300 clinicians and physicists across eight countries to standardize radiotherapy protocols and improve treatment quality using its Monaco planning system.

MARKET SEGMENTATION

This Latin America oncology device market research report is segmented and sub-segmented into the following categories.

By Application

• Radiation Therapy
• Chemotherapy
• Surgical Oncology
• Supportive Care
• Diagnostic Imaging

By Device Type

• Radiotherapy Equipment
• Chemotherapy Administration Devices
• Surgical Instruments
• Diagnostic Imaging Devices
• Supportive Devices

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialized Oncology Clinics
• Home Care Settings

By Technology

• Photodynamic Therapy
• Radiotherapy
• Cryoablation
• Electrochemotherapy

By Country

• Brazil
• Mexico
• Argentina
• Chile
• Rest of Latin America